Assessment of Efficacy, Safety and Tolerability of Stratamark® (Innovative Self-drying Silicone Gel) in the Treatment and Prevention of Striae Distensae
Overview
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Stratpharma AG
- Enrollment
- 272
- Primary Endpoint
- Product efficacy in treatment of stretch marks
Overview
Brief Summary
Stretch marks (striae distensae) are a form of scarring that is a natural result of pregnancy, obesity and in some instances occur due to puberty or steroid use. For some people, the stretch marks do not cause a problem, but in many circumstances they can cause physical symptoms such as itchiness, tenderness and pain. For many people stretch marks are also embarrassing and can have detrimental effects on a patient's mood and self-esteem. Stretch marks that result from pregnancy most commonly occur on the abdomen, breasts and thighs.
Topical silicone gel was developed nearly thirty years ago to be used in the treatment of widespread hypertrophic scars (abnormal scars, which may be red or raised/depressed itchy or painful). Since this time it has been used successfully on most scar types. . Since stretch marks are a form of scarring it is thought that topical silicone gel may be helpful for this scar type also. Stratamark™ has been developed using different forms of silicone polymers, in a gel format, that dries to form a very thin and flexible silicone gel sheet making it a convenient therapy for the treatment and prevention of stretch marks.
The aim of this clinical research study is to prove or disprove the efficacy, safety and tolerability of Stratamark™ in the prevention and treatment of stretch marks. In addition, the knowledge gained from this study may be of benefit to many future patients
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy pregnant woman (nulliparous or multiparous) entering into their third trimester (26-28 weeks, visit 1)
- •Not having striae on their abdomen at the time of trial enrollment
- •Prevention arm -
Exclusion Criteria
- •Any significant medical or surgical conditions
- •Current medications liable to interfere with study results or change the skin's response to therapy
- •Treatment arm - Inclusion Critera:
- •Confirmed SD on their abdomen post-delivery
- •Treatment arm - Exclusion Criteria:
- •Any significant medical or surgical conditions
- •Current medications liable to interfere with study results or change the skin's response to therapy
Outcomes
Primary Outcomes
Product efficacy in treatment of stretch marks
Time Frame: 6 months
Investigator-assessed improvement in stretch marks severity of patients treated with Stratamark from baseline to last assessment. Measurement tool: likert scale for stretch marks severity (0 to 6 - 0 being no stretch marks and 6 being severe).
Product efficacy in prevention of stretch marks
Time Frame: 5 months
Investigator-assessed prevalence of stretch marks in the patients treated with Stratamark vs. a literature-based control group. Measurement tool: dichotomous scale for the occurrence of stretch marks (0 no stretch marks - 1 appearance of stretch marks).
Secondary Outcomes
- Product efficacy in treatment of stretch marks(6 months)
- Severity of stretch marks developed in prevention(5 months)
- Patient product evaluation in treatment of stretch marks(6 months)
- Patient evaluation of stretch marks in treatment(6 months)
- Patient product evaluation in prevention of stretch marks(5 months)